DUBLIN, IRELAND — October 16th 2023 —Deciphex, a trailblazer in digital pathology solutions, is delighted to announce a successful €10m venture debt financing round. This strategic investment will fuel the company's capacity growth, headcount increase, service enhancement, and expansion to new markets, addressing the growing global demand in pathology services.
Founder and CEO of Deciphex, Donal O’Shea, expressed his enthusiasm:
“This financing is a pivotal step for us in our mission to transform pathology through digital innovation. It will enable us to empower more pathologists, improve service delivery, and contribute significantly to enhanced patient care and expedited drug development.”
David Bateman, Senior Partner at Claret Capital Partners, remarked:
“We are confident that our investment in Deciphex will have far-reaching impacts on the future of digital pathology. The company’s relentless dedication to innovation and excellence, and its unique approach to leveraging AI, position it at the forefront of the industry. We look forward to supporting Deciphex as it continues to break new ground and set new standards in pathology services.”
Pathology is a crucial component of health service delivery, impacting 95% of clinical care pathways, and is vital in ensuring the safety and efficacy of new drugs in development. The increasing test volumes, complexity, and declining pathologist numbers are contributing to a developing crunch point in global pathology services. Deciphex stands at the forefront of addressing this challenge, networking pathologists globally, and incorporating AI to drive efficient and high-quality reporting.
Deciphex's platforms, Diagnexia and Patholytix, are revolutionizing the field. Diagnexia provides on-demand access to remote subspecialty pathologists for primary diagnostics and secondary consult services, while Patholytix offers an industry-leading digital pathology workflow & integrated AI platform for Research Pathology, trusted by leading CROs and pharmaceutical companies.
Deciphex is a pioneering leader in digital pathology, committed to addressing the growing global demand in pathology, and integrate AI driving efficient, high-quality reporting, enhancing patient care, and accelerating drug development. With a diverse and experienced team and cutting-edge platforms like Diagnexia and Patholytix, Deciphex is set to redefine the future of pathology.
Katie Higgins
Marketing Manager
Email: [email protected]
Phone: +353 1 221 0842
Deciphex
DCU Alpha Building, Innovation Campus,
11 Old Finglas Rd, Glasnevin, Co. Dublin, D11 KXN4.
Call: +353 1 582 7193
Email: [email protected]
Twitter: @deciphex
Deciphex
DCU Alpha Building, Innovation Campus,
11 Old Finglas Rd, Glasnevin, Co. Dublin
D11 KXN4
Deciphex Inc.
500 E Diehl RoadSuite 130,
Naperville,
IL 60563
Diagnexia
Hedy Lamarr Building,
3 Babbage Way,
Exeter,
EX5 2FN
Oxford Accessioning Centre (UK)
Diagnexia UK Ltd,
Building B,
Langford Locks,
Kidlington,
OX5 1LH